However, we must be careful, for it is not possible to assess whether DualTrigger increases the risk of OHSS when compared to the GnRH agonist alone (Engmann et al., 2008).Moreover, O'Neill et al.(2016) showed that the risk of OHSS has been increasing in high responderpatients treated under the Dual Trigger strategy. The gene discussed is GNRH1; the disease is ovarian hyperstimulation syndrome.